Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAME-001 personalized neoantigen vaccine in advanced NSCLC
NL-OMON49932Phase 2Withdrawn
- Sponsor
- Frame Cancer Therapeutics
- Start
- Dec 2021
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FRAME-001 in non-small cell lung cancer (NSCLC), sponsored by Frame Cancer Therapeutics. Primary endpoint: FRAME-001-specific peripheral blood immune response. Planned start Dec 2021; status: withdrawn.
02
Drugs
FRAME-001
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON49932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49932.